Patel Shrina P, Patel Gayatri S, Suthar Jalpa V
Ramanbhai Patel College of Pharmacy, Charusat University, Anand, India.
Clin Exp Vaccine Res. 2021 May;10(2):154-170. doi: 10.7774/cevr.2021.10.2.154. Epub 2021 May 31.
The ongoing coronavirus threat from China has spread rapidly to other nations and has been declared a global health emergency by the World Health Organization (WHO). The pandemic has resulted in over half of the world's population living under conditions of lockdown. Several academic institutions and pharmaceutical companies that are in different stages of development have plunged into the vaccine development race against coronavirus disease 2019 (COVID-19). The demand for immediate therapy and potential prevention of COVID-19 is growing with the increase in the number of individuals affected due to the seriousness of the disease, global dissemination, lack of prophylactics, and therapeutics. The challenging part is a need for vigorous testing for immunogenicity, safety, efficacy, and level of protection conferred in the hosts for the vaccines. As the world responds to the COVID-19 pandemic, we face the challenge of an overabundance of information related to the virus. Inaccurate information and myths spread widely and at speed, making it more difficult for the public to identify verified facts and advice from trusted sources, such as their local health authority or WHO. This review focuses on types of vaccine candidates against COVID-19 in clinical as well as in the preclinical development platform.
来自中国的持续的冠状病毒威胁已迅速蔓延到其他国家，并被世界卫生组织（WHO）宣布为全球卫生紧急事件。这场大流行导致世界上超过一半的人口生活在封锁状态下。几家处于不同研发阶段的学术机构和制药公司已投身于针对2019冠状病毒病（COVID-19）的疫苗研发竞赛。由于该疾病的严重性、全球传播、缺乏预防措施和治疗方法，受影响个体数量不断增加，对COVID-19即时治疗和潜在预防的需求也在增长。具有挑战性的部分是需要对疫苗在宿主中的免疫原性、安全性、有效性和保护水平进行严格测试。随着世界应对COVID-19大流行，我们面临着与该病毒相关的信息过多的挑战。不准确的信息和谣言迅速广泛传播，使得公众更难从可信来源（如当地卫生当局或WHO）识别经过验证的事实和建议。本综述重点关注临床以及临床前研发平台上针对COVID-19的候选疫苗类型。
